Henry Schein Management

Management Kriterienprüfungen 2/4

Henry Schein's CEO ist Stan Bergman , ernannt in Jan 1989, hat eine Amtszeit von 35.42 Jahren. Die jährliche Gesamtvergütung beträgt $10.01M , bestehend aus 16.2% Gehalt und 83.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.59% der Aktien des Unternehmens, im Wert von $49.98M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 10.9 Jahre bzw. 11.8 Jahre.

Wichtige Informationen

Stan Bergman

Geschäftsführender

US$10.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	16.2%
Amtszeit als Geschäftsführer	35.4yrs
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	10.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Stan Bergman im Vergleich zu den Einnahmen von Henry Schein verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 30 2024	n/a	n/a	US$346m
Dec 30 2023	US$10m	US$2m	US$416m
Sep 30 2023	n/a	n/a	US$445m
Jul 01 2023	n/a	n/a	US$458m
Apr 01 2023	n/a	n/a	US$478m
Dec 31 2022	US$8m	US$2m	US$538m
Sep 24 2022	n/a	n/a	US$638m
Jun 25 2022	n/a	n/a	US$650m
Mar 26 2022	n/a	n/a	US$646m
Dec 25 2021	US$11m	US$2m	US$631m
Sep 25 2021	n/a	n/a	US$626m
Jun 26 2021	n/a	n/a	US$606m
Mar 27 2021	n/a	n/a	US$438m
Dec 26 2020	US$6m	US$751k	US$403m
Sep 26 2020	n/a	n/a	US$591m
Jun 27 2020	n/a	n/a	US$585m
Mar 28 2020	n/a	n/a	US$713m
Dec 28 2019	US$14m	US$1m	US$701m
Sep 28 2019	n/a	n/a	US$488m
Jun 29 2019	n/a	n/a	US$444m
Mar 30 2019	n/a	n/a	US$438m
Dec 29 2018	n/a	n/a	US$431m
Sep 29 2018	n/a	n/a	US$304m
Jun 30 2018	n/a	n/a	US$352m
Mar 31 2018	n/a	n/a	US$377m

Vergütung im Vergleich zum Markt: StanDie Gesamtvergütung ($USD10.01M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD3.34M).

Entschädigung vs. Einkommen: StanDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Stan Bergman (74 yo)

35.4yrs

Amtszeit

US$10,005,729

Vergütung

Mr. Stanley M. Bergman, also known as Stan, has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989 and has been its Executive Director since 1982. Mr. Bergman served a...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Stanley Bergman	Executive Chairman & CEO	35.4yrs	US$10.01m	0.59% $ 50.8m
James Breslawski	President	19.1yrs	US$2.69m	0.11% $ 9.6m
Ronald South	Senior VP & CFO	2.2yrs	US$2.35m	0.0078% $ 668.4k
Michael Ettinger	Executive VP & COO	1.9yrs	US$2.97m	0.019% $ 1.6m
Mark Mlotek	Executive VP	12.4yrs	US$3.22m	0.011% $ 982.9k
Olga Timoshkina	VP of Corporate Finance	2.8yrs	keine Daten	keine Daten
Christopher Pendergast	Senior VP & CTO	6.2yrs	keine Daten	keine Daten
Graham Stanley	VP of Investor Relations & Strategic Finance Project Officer	no data	keine Daten	keine Daten
Walter Siegel	Senior VP & Chief Legal Officer	10.7yrs	keine Daten	0.031% $ 2.7m
Ann Gothard	Vice President of Global Corporate Media Relations	no data	keine Daten	keine Daten
Lorelei McGlynn	Senior VP & Chief Human Resources Officer	11.1yrs	keine Daten	0.073% $ 6.3m
Gerard Meuchner	Chief Global Communications Officer & VP	12.3yrs	keine Daten	keine Daten

10.9yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: 0L3CDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (10.9 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Stanley Bergman	Executive Chairman & CEO	42.4yrs	US$10.01m	0.59% $ 50.8m
Mark Mlotek	Executive VP	28.8yrs	US$3.22m	0.011% $ 982.9k
Philip Laskawy	Independent Lead Director	22.3yrs	US$335.40k	0.029% $ 2.5m
Joseph Herring	Independent Director	8.1yrs	US$313.00k	0.017% $ 1.5m
Louis Sullivan	Chairman of Medical Advisory Board	17.9yrs	US$225.87k	keine Daten
Norman Matthews	Member of Medical Advisory Board	no data	US$277.90k	keine Daten
Bradley Sheares	Independent Director	14.4yrs	US$304.20k	0.0026% $ 224.8k
Carol Raphael	Independent Director	11.8yrs	US$282.60k	0.023% $ 2.0m
Kurt Kuehn	Independent Director	8.1yrs	US$316.40k	0.0014% $ 118.0k
Deborah Derby	Independent Director	3.3yrs	US$304.80k	0.00059% $ 50.8k
Mohamad Ali	Independent Director	3.3yrs	US$271.60k	0.0060% $ 512.5k
Anne Margulies	Independent Director	6yrs	US$291.40k	0.015% $ 1.3m

11.8yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: 0L3CDie Vorstandsmitglieder sind sehr erfahren ( 11.8 ).

Henry Schein Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Insider recently sold US$478k worth of stock

Henry Schein Appoints Carole T. Faig as New Independent Director

Insider recently sold US$835k worth of stock

Executive VP recently sold US$1.9m worth of stock

Recent updates

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.72 (vs US$0.92 in 1Q 2023)

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Insider recently sold US$478k worth of stock

Full year 2023 earnings released: EPS: US$3.19 (vs US$3.95 in FY 2022)

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: US$1.07 (vs US$1.17 in 2Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently sold US$835k worth of stock

Executive VP recently sold US$1.9m worth of stock

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: EPS: US$0.92 (vs US$1.32 in 1Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Independent Director recently sold US$148k worth of stock

Independent Lead Director recently sold US$504k worth of stock

Now 20% undervalued after recent price drop

Independent Director recently sold US$923k worth of stock

Full year 2022 earnings released: EPS: US$3.95 (vs US$4.51 in FY 2021)

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insider recently sold US$1.2m worth of stock

Henry Schein, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Henry Schein, Inc. Announces its Lineup of Products and Solutions At the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 Through September 17

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Midway Dental Supply, Inc.

Henry Schein, Inc. Announces the Passing of Board Member E. Dianne Rekow

Second quarter 2022 earnings released: EPS: US$1.17 (vs US$1.11 in 2Q 2021)

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year 2022

Henry Schein, Inc. Appoints Mark Hillebrandt as Chief Digital Revenue Officer

Henry Schein, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Condor Dental Research Company SA from MCCB Holding Sarl.

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from Russell 1000 Dynamic Index

Henry Schein, Inc. (NasdaqGS:HSIC) entered into a definitive agreement to acquire Condor Dental Research Company SA from MCCB Holding Sarl.

Insider recently sold US$982k worth of stock

Henry Schein, Inc. Appoints Dirk Benson as Chief Commercial Officer of North America Distribution Group

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$1.32 (vs US$1.17 in 1Q 2021)

Henry Schein, Inc. to Report Q1, 2022 Results on May 03, 2022

Henry Schein Inc. Announces Executive Changes, Effective from July 1, 2022

Henry Schein Promotes Jennifer Ferrero to Corporate Secretary, Effective July 1, 2022

Executive VP recently sold US$2.0m worth of stock

Henry Schein to Showcase A Wide Portfolio of Products, Services, and Solutions During the Chicago Midwinter Dental Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

Henry Schein, Inc. Announces Lineup of New Products and Solutions At the Greater New York Dental Meeting

Third quarter 2021 earnings released: EPS US$1.16 (vs US$1.00 in 3Q 2020)

Henry Schein, Inc. Announces Not to Provide Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.08 loss in 2Q 2020)

Henry Schein, Inc. (NasdaqGS: HSIC) acquired 70% stake in eAssist Dental Solutions, Inc.

Independent Director has left the company

Independent Director has left the company

Independent Director recently sold US$237k worth of stock

First quarter 2021 earnings released: EPS US$1.17 (vs US$0.91 in 1Q 2020)